Skip to content
10-K

Annual Report

Phio Pharmaceuticals Corp PHIO

0001437749-26-007078

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 11.62M sh
Capex FY 2025 · Dec 31, 2025 $12K
Capex FY 2025 · Dec 31, 2024 $1K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$7.98M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$7.11M
Cash And Equivalents FY 2025 · Dec 31, 2025 $21.03M
Cash And Equivalents FY 2025 · Dec 31, 2024 $5.38M
Stockholders Equity FY 2025 · Dec 31, 2025 $20.15M
Stockholders Equity FY 2025 · Dec 31, 2024 $4.72M
Stockholders Equity FY 2025 · Dec 31, 2023 $7.73M
Total Liabilities FY 2025 · Dec 31, 2025 $1.34M
Total Liabilities FY 2025 · Dec 31, 2024 $1.02M
Current Assets FY 2025 · Dec 31, 2025 $21.48M
Current Assets FY 2025 · Dec 31, 2024 $5.74M
Total Assets FY 2025 · Dec 31, 2025 $21.49M
Total Assets FY 2025 · Dec 31, 2024 $5.74M
Eps Basic FY 2025 · Dec 31, 2025 −$1.45
Eps Basic FY 2025 · Dec 31, 2024 −$9.08
Sga Expense FY 2025 · Dec 31, 2025 $4.6M
Sga Expense FY 2025 · Dec 31, 2024 $3.74M
Rd Expense FY 2025 · Dec 31, 2025 $4.62M
Rd Expense FY 2025 · Dec 31, 2024 $3.64M
Net Income FY 2025 · Dec 31, 2025 −$8.7M
Net Income FY 2025 · Dec 31, 2024 −$7.15M
Operating Income FY 2025 · Dec 31, 2025 −$9.22M
Operating Income FY 2025 · Dec 31, 2024 −$7.39M